You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Funded Biomarker Testing

Find an overview of funded biomarker testing in Ontario. Information listed includes diagnostic, predictive and prognostic markers, as well as a summary of testing sites.

Disponible en anglais seulement. Vous pouvez demander un version française.

Funded Biomarker Testing

44 items

Assessment of gene amplification (e.g. MDM2, CDK4, BCOR)

Funded Biomarker Disease Site:
Biomarker:
Testing Method:FISH, Array, and/or Sequencing
Testing Site: Hamilton Health Sciences, London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, The Ottawa Hospital

BRAF testing should be performed for colorectal cancer cases with abnormal MLH1 results.

Funded Biomarker Disease Site: Colorectal
Biomarker: BRAF
Testing Method:Panel
Testing Site: Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Mount Sinai Hospital, The Ottawa Hospital, Trillium Health Partners, University Health Network

Immunohistochemical evaluation, where indicated, to assess line of differentiation for classification

Funded Biomarker Disease Site: Soft Tissue
Biomarker:
Testing Method:Immunohistochemistry (IHC)
Testing Site: Hamilton Health Sciences, London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, The Ottawa Hospital

Molecular interrogation, where indicated, for classification, prognostic and/or therapeutic purposes.

Funded Biomarker Disease Site: Soft Tissue
Biomarker: Refer to 2023 Consensus Pathology Recommendations for Mesenchymal Tumours of Soft Tissue and Bone
Testing Method:Sequencing
Testing Site: Mount Sinai Hospital, The Ottawa Hospital

Newly diagnosed cases of cervical carcinoma where HPV cannot be determined from histology/p16 staining.

Funded Biomarker Disease Site: Cervix
Biomarker: HPV
Testing Method:Immunohistochemistry (IHC)
Testing Site: Hamilton Health Sciences, Health Sciences North, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, University Health Network

Newly diagnosed cases of penile carcinoma where HPV cannot be determined from histology/p16 staining.

Funded Biomarker Disease Site: Penile
Biomarker: HPV
Testing Method:In Situ Hybridization (ISH)
Testing Site: Hamilton Health Sciences, Health Sciences North, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, University Health Network

Newly diagnosed cases of squamous cell carcinoma where HPV cannot be determined from histology/p16 staining.

Funded Biomarker Disease Site: Head and Neck
Biomarker: HPV
Testing Method:In Situ Hybridization (ISH)
Testing Site: Health Sciences North, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, Sunnybrook Health Sciences Centre, University Health Network

Promoter Methylation testing should be performed for all MMR cases with abnormal MLH1 results*.

Funded Biomarker Disease Site: Adrenal Gland, Bladder/ Urothelial, Colorectal, Endometrium, Esophagus, Hepatobiliary, Ocular, Ovary, Pancreas, Skin, Small Bowel, Stomach
Biomarker: MLH1 Methylation
Testing Method:Methylation
Testing Site: Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Mount Sinai Hospital, Trillium Health Partners, University Health Network

Reflex testing for all newly diagnosed paragangliomas (to inform need for germline testing)

Funded Biomarker Disease Site: Multiple Disease Sites
Biomarker: SDHB
Testing Method:Immunohistochemistry (IHC)
Testing Site: London Health Sciences Centre, Mount Sinai Hospital, Sunnybrook Health Sciences Centre, University Health Network, William Osler Health System

Reflex testing for the diagnosis of serous tumours (epithelial ovarian, fallopian tube, peritoneal cancers) when needed to establish histologic subtype.

Funded Biomarker Disease Site: Ovary
Biomarker: p53, WT1
Testing Method:Immunohistochemistry (IHC)
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, North Bay Regional Health Centre, North York General Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System

Reflex testing on all metastatic thyroid cancer, including sporadic medullary and radio-iodine refractory well differentiated thyroid cancer.

Funded Biomarker Disease Site: Thyroid
Biomarker: BRAF, HRAS, NRAS, NTRK3, PPARG, RET, KRAS
Testing Method:Panel
Testing Site: Kingston Health Sciences Centre, London Health Sciences Centre, Mount Sinai Hospital, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System

Reflex testing on all newly diagnosed breast cancers.

Funded Biomarker Disease Site: Breast
Biomarker: HER2, ER, PR
Testing Method:Immunohistochemistry (IHC)
Testing Site: Grand River Hospital, Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, Lakeridge Health, London Health Sciences Centre, Mount Sinai Hospital, North York General Hospital, Royal Victoria Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Thunder Bay Regional Health Sciences Centre, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System, Windsor Regional Hospital

Pages